Mydimed
Solutions for Predicting and Preventing Adverse Drug Reactions
Company Overview
Snapshot
Founded in September 2016 by Yuval Eyal, Mydimed operates with 1–10 employees. The company secured seed funding in January 2017 from Samurai Incubate Israel.
Business overview
Mydimed develops algorithms and software tools to predict and prevent adverse drug reactions (ADRs) in high-risk, poly-pharmacy patients. The company leverages artificial intelligence and proprietary algorithms to analyze medical records, aiming to reduce morbidity and mortality. Mydimed's technology focuses on deriving insights from electronic medical records to optimize the prediction of high-risk ADRs that could lead to hospitalization or readmission, serving healthcare providers and pharmaceutical companies in the Health Tech & Life Sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Mydimed's primary focus?
- Mydimed develops algorithms and software tools designed to predict and prevent adverse drug reactions (ADRs) among high-risk, poly-pharmacy patients.
- When was Mydimed founded?
- Mydimed was founded in September 2016.
- Who is a key founder of Mydimed?
- Yuval Eyal is a co-founder and CEO of Mydimed.
- What technology does Mydimed utilize?
- Mydimed utilizes artificial intelligence and proprietary algorithms to derive insights from medical records for predicting and preventing adverse drug reactions.
- What was a significant early funding event for Mydimed?
- In January 2017, Mydimed received seed funding from Samurai Incubate Israel.